IS5177A - Notkun 5-(4-(2-(N-metýl-N-(2-pýridýl)amínó)-etoxý)bensýl)2.4-þíasólídíndíons við meðferð á fjölblöðrueggjastokkaheilkennum og þungunarsykursýki - Google Patents

Notkun 5-(4-(2-(N-metýl-N-(2-pýridýl)amínó)-etoxý)bensýl)2.4-þíasólídíndíons við meðferð á fjölblöðrueggjastokkaheilkennum og þungunarsykursýki

Info

Publication number
IS5177A
IS5177A IS5177A IS5177A IS5177A IS 5177 A IS5177 A IS 5177A IS 5177 A IS5177 A IS 5177A IS 5177 A IS5177 A IS 5177A IS 5177 A IS5177 A IS 5177A
Authority
IS
Iceland
Prior art keywords
thiazolidinedione
pyridyl
ethoxy
benzyl
amino
Prior art date
Application number
IS5177A
Other languages
English (en)
Inventor
Antonucci Tammy
Lockwood Dean
Norris Rebecca
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of IS5177A publication Critical patent/IS5177A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS5177A 1997-05-15 1999-09-10 Notkun 5-(4-(2-(N-metýl-N-(2-pýridýl)amínó)-etoxý)bensýl)2.4-þíasólídíndíons við meðferð á fjölblöðrueggjastokkaheilkennum og þungunarsykursýki IS5177A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/856,987 US5874454A (en) 1993-09-15 1997-05-15 Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
PCT/US1998/010113 WO1998051305A1 (en) 1997-05-15 1998-05-14 Use of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)-ethoxy)benzyl)2,4-thiazolidinedione in the treatment of polycystic ovary syndrome and gestational diabetes

Publications (1)

Publication Number Publication Date
IS5177A true IS5177A (is) 1999-09-10

Family

ID=25324901

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5177A IS5177A (is) 1997-05-15 1999-09-10 Notkun 5-(4-(2-(N-metýl-N-(2-pýridýl)amínó)-etoxý)bensýl)2.4-þíasólídíndíons við meðferð á fjölblöðrueggjastokkaheilkennum og þungunarsykursýki

Country Status (14)

Country Link
US (1) US5874454A (is)
EP (1) EP0981346A1 (is)
JP (1) JP2001525827A (is)
KR (1) KR20010012556A (is)
AU (1) AU731690B2 (is)
BR (1) BR9809120A (is)
CA (1) CA2282473A1 (is)
HU (1) HUP0003397A3 (is)
IL (1) IL132125A0 (is)
IS (1) IS5177A (is)
NO (1) NO995549L (is)
PL (1) PL336764A1 (is)
WO (1) WO1998051305A1 (is)
ZA (1) ZA984084B (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
GB0019223D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0021865D0 (en) * 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
PL2068909T3 (pl) 2007-03-30 2012-09-28 Ambrx Inc Modyfikowane polipeptydy fgf-21 i ich zastosowanie
ES2344183B1 (es) * 2009-02-18 2011-06-10 Italfarmaco, S.A. Uso de agentes sensibilizantes a insulina por via vaginal.
US9339458B2 (en) * 2009-02-18 2016-05-17 Itf Research Pharma, S.L.U. Use of vaginal insulin sensitizing agents
JP6702962B2 (ja) 2014-10-24 2020-06-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改変ｆｇｆ−２１ポリペプチドおよびその使用
RU2665969C1 (ru) * 2017-05-04 2018-09-05 Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) Способ лечения синдрома поликистозных яичников

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5120754A (en) * 1988-03-08 1992-06-09 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US4897405A (en) * 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
JP3544659B2 (ja) * 1990-02-09 2004-07-21 ファルマシア・アンド・アップジョン・カンパニー インスリン感性化剤類の高血圧治療のための使用
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
WO1993000343A1 (en) * 1991-06-25 1993-01-07 Pfizer Inc. Thiazolidinedione hypoglycemic agents
RU2195282C2 (ru) * 1993-09-15 2002-12-27 Санкио Компани Лимитед Применение тиазолидиндионов для предотвращения или отдаления наступления инсулиннезависимого сахарного диабета (niddm)
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus

Also Published As

Publication number Publication date
CA2282473A1 (en) 1998-11-19
ZA984084B (en) 1998-11-20
IL132125A0 (en) 2001-03-19
NO995549D0 (no) 1999-11-12
KR20010012556A (ko) 2001-02-15
AU7494998A (en) 1998-12-08
HUP0003397A3 (en) 2002-02-28
JP2001525827A (ja) 2001-12-11
AU731690B2 (en) 2001-04-05
NO995549L (no) 1999-11-12
EP0981346A1 (en) 2000-03-01
WO1998051305A1 (en) 1998-11-19
US5874454A (en) 1999-02-23
PL336764A1 (en) 2000-07-17
BR9809120A (pt) 2000-08-01
HUP0003397A2 (hu) 2002-01-28

Similar Documents

Publication Publication Date Title
IS5194A (is) Notkun þíasólídíndíonafleiða við meðferð á fjölblöðrueggjastokkaheilkennum og þungunarsykursýki
NO2014014I2 (no) Macitentan, propylsulfamsyre [5-(4-brom-fenyl)-6-[2-(5-brom-pyrimidin-2-yloksy)-etoksy]-pyrimidin-4-yl]-amid eller et farmasøytisk akseptabelt salt derav; blant annet kravene 1, 5, 6 og 10 I søknaden (se vedlegg)
IS5177A (is) Notkun 5-(4-(2-(N-metýl-N-(2-pýridýl)amínó)-etoxý)bensýl)2.4-þíasólídíndíons við meðferð á fjölblöðrueggjastokkaheilkennum og þungunarsykursýki
DK1228067T3 (da) 5-leddede heterocykliske forbindelser med hypoglykæmisk og hypolipidæmisk virkning
DE69839021D1 (de) Neuartige exendin agonisten
NO996266L (no) Behandling av diabetes tiazolidindion og metformin
ATE396738T1 (de) Verwendung von glp-2-peptiden
ATE302202T1 (de) Hcl-salze von 5-(4-(2-(n-methyl-n-(2- pyridyl)amino)ethoxy)benzyl)thiazolidin-2,4-dio
NO953678D0 (no) Smart-kort, spesielt til bruk ved telefoni og lignende
NO2009002I1 (no) 5-{4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl}tiazolidin-2,4-dionmaleat(salter/solvater)+glimepirid
PE99599A1 (es) Composicion farmaceutica para el tratamiento de la diabetes
ID24744A (id) Hidrat dari garam asam 5- [4- (n-metil-n- (2-piridil)amino) etoksi] benzil] tiazolidin-2,4-dion maleat
IL120443A0 (en) Heterocyclic compounds for the treatment of pancreatitis
CY1105252T1 (el) Το υδροχλωρικο αλας της 5-[4-[2-(ν-μεθυλο-ν-(2-πυριδυλο)αμινο)-αιθοξυ]βενζυλο]θειαζολιδινο-2,4-διονης
DZ2510A1 (fr) Composition comprenant de la 5-Ä4-Ä2-(n-méthyl-n-(2-pyridyl)amino)éthoxyÜbenzylÜthiazolidine-2,4-dione et procédé pour sa préparation.
RS50136B (sr) Derivati tiazolidindiona i njihova upotreba kao antidijabetika
CY1105354T1 (el) Ένα παραγωγο θειαζολιδινοδιονης και η χρηση του σαν αντι-διαβητικο
BR0002399B1 (pt) dispositivo de armazenamento de registro de transaÇço e mÁquina de transaÇço incluindo o mesmo.
CY1107252T1 (el) Τρυγικο αλας παραγωγου της θειζολιδινοδιονης
DK1349855T3 (da) 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)thiazolidin-2,4-dionmesylatsalt
AU5533300A (en) Novel 4-(2-oxodihydrooxadiazinylphenyl)amides and the use thereof for treating anemia
IL153280A0 (en) 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4 dione hydriodide as pharmaceutical
NO20014393L (no) 1,3,4-oksadiazol-derivater og fremgangsmåte for fremstilling av disse
AU2002352481A1 (en) 5- (4- (2- (n-methyl-n- (2-pyridil) amino) ethoxy) benzyl) thiazolidine-2, 4-dione nephtalenesulfonate salt and use against diabetes mellitus
BR9805392B1 (pt) processo para produção de 2-(metiltio)-5-(trifluorometil)-1,3,4-tiadiazol usando metilditiocarbazinato e ácido trifluoroacético.